Jacobs Levy Equity Management Inc. Takes $721,000 Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Jacobs Levy Equity Management Inc. bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 202,030 shares of the company's stock, valued at approximately $721,000. Jacobs Levy Equity Management Inc. owned approximately 0.32% of Fulcrum Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in FULC. National Bank of Canada FI grew its position in shares of Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock worth $28,000 after buying an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock valued at $43,000 after acquiring an additional 4,701 shares during the last quarter. SG Americas Securities LLC grew its holdings in Fulcrum Therapeutics by 26.5% during the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company's stock worth $118,000 after acquiring an additional 6,926 shares during the period. Profund Advisors LLC bought a new stake in shares of Fulcrum Therapeutics during the 2nd quarter valued at $68,000. Finally, American Century Companies Inc. lifted its stake in shares of Fulcrum Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 104,371 shares of the company's stock valued at $647,000 after purchasing an additional 12,167 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on FULC. Stifel Nicolaus lowered Fulcrum Therapeutics from a "buy" rating to a "hold" rating and decreased their target price for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. HC Wainwright reissued a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 12th. Royal Bank of Canada reissued a "sector perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Finally, Bank of America cut shares of Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and lowered their price objective for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Fulcrum Therapeutics presently has an average rating of "Hold" and a consensus target price of $9.33.

Fulcrum Therapeutics Stock Up 1.0 %

FULC traded up $0.04 during trading on Tuesday, hitting $4.05. The company had a trading volume of 784,723 shares, compared to its average volume of 983,803. The company has a market capitalization of $218.45 million, a PE ratio of -12.94 and a beta of 2.14. Fulcrum Therapeutics, Inc. has a one year low of $2.86 and a one year high of $13.70. The firm's 50-day moving average price is $3.48 and its 200 day moving average price is $6.01.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.